Chondrosarcoma of the nasal septum is a rare entity with 5-10% arising from the head and neck region. Differentiating benign cartilaginous tumors such as chondromas from low-grade chondrosarcomas can be challenging. We report a 45-year-old female who presented to us with bilateral nasal obstruction. A contrast-enhanced computed tomography and multiple deep biopsies were performed which were suggestive of grade 1 chondrosarcoma. The patient subsequently underwent endoscopic excision of the tumor with adequate margins confirmed by histopathology. The patient is on regular follow-up and has shown no evidence of recurrence on diagnostic nasal endoscopy and radiological imaging.
Introduction
Chondrosarcomas are rare tumors known to arise from cartilage, 5-10% arising from the head and neck region and laryngeal cartilage being the most predominant site of origin [1, 2] . Surgery is considered as the primary treatment for chondrosarcoma. However, due to considerable risk of morbidity and unavoidable cosmetic problems, open approaches are avoided unless indicated. Endoscopic removal should be considered in cases when the tumor is limited to the nasal cavity. A review of the literature from 1927 to date lists approximately 63 cases of chondrosarcoma originating from the nasal septum [3] .
Case Report
A 42-year-old woman presented with a 5-month history of bilateral nasal obstruction (left > right), persistent headache, anosmia, and left epiphora. There was no history of nasal discharge, epistaxis, loss of vision, diplopia, facial pain, facial swelling, fever, or weight loss. There was no similar history in the family. Nasal endoscopy revealed the presence of a firm, smooth, fleshy nontender intranasal mass filling both the nasal cavities. The mass did not bleed on touch and could not be separated from the adjacent septum. The nasopharynx appeared normal with patent eustachian tube bilaterally. Intraorally, there was a bulge over the hard palate (left > right) which was covered by normal mucosa. Her ocular movements were normal and otoscopic examination was unremarkable. There were no palpable cervical lymph nodes. General and systemic examinations were normal.
Contrast-enhanced CT scan of the nasal cavity and paranasal sinuses revealed a minimally enhancing homogenous soft tissue mass in the left nasal cavity, filling the anterior part of the nasal cavity with thinning of the left lateral nasal wall and extension into the right nasal cavity ( Fig. 1) . Posteriorly, the bony septum was intact. There was no evidence of bone destruction. Histopathology revealed cartilaginous tissue comprising lobules of chondrocytes embedded in chondroid matrix with intervening fibroconnective tissue (Fig. 3) . The lobules were moderately cellular composed of chondrocytes in groups as well as singly scattered. The chondrocytes showed mild to moderate pleomorphism, enlarged nuclei, and hyperchromasia. The fibroconnective stroma showed focal invasion by the neoplastic chondrocytes suggesting the possibility of grade 1 chondrosarcoma (Fig. 4) . The patient had a satisfactory cosmetic outcome and did not require any surgical reconstruction. The patient is under follow-up every 6 months for the past 1 year and 5 months with no evidence of recurrence on diagnostic nasal endoscopy. 
Discussion
Chondrosarcomas are nonepithelial malignant tumors most commonly involving the pelvis, femur, and humerus with only 5-10% located in the head and neck, most commonly in the larynx, maxilla, mandible, and skull base [2, 4, 5] . The usual age of presentation varies between 40 and 50 years, with higher incidence among men [6] .
The diagnosis of chondrosarcomas is made histologically, and they are categorized into three grades on the basis of the degree of cellularity, nuclear size and atypia, and mitotic activity. Grade 1 chondrosarcomas have abundant chondroid matrix, clusters of chondrocytes with normal or slightly enlarged nuclei, rare nucleoli, absent mitoses, and occasional binucleation. Grade 2 chondrosarcomas, on the other hand, appear to have less chondroid matrix and more chondrocytes than grade 1 tumors with presence of rare mitoses, slightly enlarged vesicular hyperchromatic nuclei, and multinucleation. Grade 3 chondrosarcomas display a myxoid matrix with irregularly shaped chondrocytes and increased cellularity, nuclear pleomorphism, and mitoses compared with the low-grade chondrosarcomas [2, 7] .
Head and neck chondrosarcomas may be initially misdiagnosed as chondromas due to sampling errors, making the diagnosis difficult [8] . Gallagher and Strome [9] in 1972 stressed the need for several intranasal biopsies to confirm the diagnosis of sarcoma.
F-18 fluoro-2-deoxyglucose positron emission tomography ( 18 F-FDG PET) has been reported to help in cartilaginous tumor grading and outcome prediction. When the maximum SUV cutoff of 2.0 was used to distinguish benign and malignant cartilage neoplasms in 26 operated cartilaginous tumors, the sensitivity of 18 F-FDG PET was 90.9%, specificity 100%, and accuracy 96.6% [10] .
Chondrosarcomas are known to be relatively radioresistant, making surgery the primary option for treatment. Extensive disease warrants en bloc removal by open approaches which include lateral rhinotomy, anterior craniofacial resection, and Le Fort I down fracture. We chose transnasal endoscopic removal of the tumor, considering the mass was restricted within the nasal cavity, with safe resectable margins and a low rate of distant metastasis (low-grade chondrosarcoma).
To enhance radiosensitivity of grade II chondrosarcomas and to enhance the synergistic effect on apoptosis of the tumor, dual gene slicing technology has been implemented [11] . Some oncological institutes have imple-mented proton and carbon ion radiation in the treatment of chondrosarcoma considering its high local control, excellent precision, rapid delivery of high radiation doses, and low toxicity [12, 13] .
Conclusion
A rare case of nasal septum chondrosarcoma was successfully treated by endoscopic nasal surgery. This approach could represent a safe and potentially curative treatment for this malignant tumor. We believe that transnasal endoscopic removal for this type of tumor should be implemented as a primary option in the future, even for more extensive cases.
